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Novelty and Impact 
DNA damage response (DDR) activation is common in gastric cancer (GC) and possibly fuelled by  
mutations affecting DNA damage repair ability (e.g. TP53 and ARID1A). The subset of GC patients 
carrying activation of the DDR had adverse survival outcomes compared with their negative 
counterparts. TP53 mutations did not modify the relationship between DDR biomarkers and inferior 
clinical outcomes, whereas ARID1A mutations did. Overall, this study identifies molecular factors 
associated with the efficacy of chemotherapy.  
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Abstract 
The DNA damage response (DDR) network is exploited by cancer cells to withstand chemotherapy. 
Gastric cancer (GC) carries deregulation of the DDR and harbors genetic defects that fuel its 
activation. The ATM-Chk2 and ATR-Chk1-Wee1 axes are deputed to initiate DNA repair. Over-
activation of these pathways in cancer cells may represent an adaptive response for compensating 
genetic defects deregulating G1-S transition (e.g. TP53) and ATM/ATR-initiated DNA repair (e.g. 
ARID1A).  We hypothesized that DDR-linked biomarkers may predict clinical outcomes in GC 
patients treated with chemotherapy. Immunohistochemical assessment of DDR kinases (pATM, 
pChk2, pChk1 and pWee1) and DNA damage markers (γ-H2AX and pRPA32) was performed in 
biological samples from 110 advanced GC patients treated with first-line chemotherapy, either in 
phase II trials or in routine clinical practice. In 90 patients this characterization was integrated with 
targeted ultra-deep sequencing for evaluating the mutational status of TP53 and ARID1A. We 
recorded a positive association between the investigated biomarkers. The combination of two 
biomarkers (γ-H2AX
high
/pATM
high
) was an adverse factor for both progression-free survival 
(multivariate Cox: HR 2.23, 95%CI: 1.47-3.40) and overall survival (multivariate Cox: HR: 2.07, 
95%CI: 1.20-3.58). The relationship between the γ-H2AX
high
/pATM
high
 model and progression-free 
survival was consistent across the different TP53 backgrounds and was maintained in the ARID1A 
wild-type setting. Conversely, this association was no longer observed in an ARID1A-mutated 
subgroup.  The γ-H2AX
high
/pATM
high
 model negatively impacted survival outcomes in GC patients 
treated with chemotherapy. The mutational status of ARID1A, but apparently not TP53 mutations, 
affects its predictive significance.   
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INTRODUCTION 
DNA damage and repair (DDR) pathways protect eukaryotic cells from genotoxic injuries ensuring 
the transmission of an unaltered genetic code to the progeny.
1
 This complex genome-protecting 
network is aberrantly exploited by cancer cells to tolerate the high levels of DNA damage they 
accumulate. Indeed, the genome of cancer cells is threatened by a variety of endogenous substances 
and deregulated processes, including: i) the elevated production of reactive oxygen species related 
to the increased metabolic demands (oxidative DNA damage),
2
  ii) the replicative stress imposed by 
activating mutations in oncogenes that control cell proliferation,
3
  and iii) the defective nature of the 
G1/S checkpoint (e.g. TP53 mutations) that renders cancer cells “addicted” to intact cell cycle 
control systems for determining cell fate upon DNA damage.
4
   
The crosstalking Ataxia-Telangiectasia Mutated (ATM)-Checkpoint Kinase 2 (Chk2) and ataxia 
telangiectasia and Rad3-related protein (ATR)-Checkpoint kinase 1 (Chk1)-Wee1-like protein 
kinase (Wee1) axes operate in the intra-S and G2/M checkpoints.
5,6
  When DNA single-  and 
double-strand breaks (SSBs and DSBs) occur, ATR-Chk1-Wee1 and ATM-Chk2 pathways halt the 
cell cycle and coordinate DNA repair or self-elimination of irreversibly damaged cells, depending 
upon the entity of the damage and repair capabilities.
5
  In cancer cells DNA damage often arises in a 
background of defective G1/S transition; within this molecular frame activation of ATM-Chk2 and 
ATR-Chk1-Wee1 pathways becomes crucial to avoid entry into a defective and lethal mitosis. We 
hypothesized that this adaptive response may represent a sort of “molecular side effect” through 
which cancer cells are predisposed to efficiently handle exogenous (therapeutic) sources of DNA 
damage, such as chemotherapy.
7,8
 
Molecular characterization of gastric cancer (GC) revealed ATM/ATR activation across all the 
molecular subtypes.
9
  Moreover, a number of genes associated with their signaling are recurrently 
altered in GC, including genes linked to defective cell cycle control (e.g. TP53)  and altered 
initiation of the DDR cascade (e.g. ARID1A).
9
   We reasoned that aberrant activation of the DDR in 
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GC, supposedly driven or enforced by the underlying genetic portrait of the disease, may be 
exploited in the search for biomarkers predicting chemotherapy sensitivity/resistance. To test this 
hypothesis, biological samples from 110 GC patients treated with first-line chemotherapy in 
prospective phase II trials or in routine clinical practice,
10-13
 were retrospectively evaluated by 
immunohistochemistry (IHC) for assessing the expression of DDR kinases (pATM, pChk2, pChk1 
and pWee1) and DNA damage markers, namely the DNA DSB marker phosphorylated H2A 
Histone Family Member X (γ-H2AX) and the single-stranded DNA/SSB marker phosphorylated 
replication protein A2 (pRPA2, best known as pRPA32). Mutation analysis of TP53 and ARID1A 
was conducted in 90 patients to investigate whether specific genetic events with elevated mutational 
rates impacted the predictive significance of most promising markers.  
PATIENTS AND METHODS  
Patients  
Written informed consents were obtained by all the participants. The study was conducted in 
accordance with the Declaration of Helsinki and approved by the Ethics Committee of the “Regina 
Elena” National Cancer Institute of Rome. This study adheres to the REMARK guidelines.
14
  For 
this analysis, 110 patients with histologically confirmed, inoperable locally advanced or metastatic 
cancer of the stomach or gastroesophageal junction who received first-line chemotherapy 
(December 2000-January 2015) were included. Median follow-up was 11 months (IQR 5-20 
months). Patients were considered eligible if complete data on clinical features and treatment 
outcomes were available and the amount of biological materials  from biopsies or surgical samples 
was sufficient for testing the entire panel of antibodies. Following trastuzumab approval for the 
treatment of GC patients,
15
  HER2 overexpression/amplification was carried out in 20 patients. 
Chemotherapy regimens and schedules are detailed in Suppl. Table 1. Tumor responses were 
evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) criteria v.1.1.  Progression-
free survival (PFS) was calculated as the time between the first cycle of chemotherapy until 
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radiological evidence of disease progression or death due to any cause. Overall survival (OS) was 
computed as the time from the first cycle of chemotherapy to death due to any cause. 
Immunohistochemistry  
The immunohistochemical assessment of γ-H2AX, pATM, pChk2, pRPA32, pChk1 and pWee1was 
performed in formalin-fixed paraffin-embedded (FFPE) tissues with the following antibodies: anti-
phospho-H2AX (Ser139) (clone JBW301) mouse monoclonal antibody (MAb) (Upstate) at the 
dilution of 1:500 (pH8), anti-phospho-ATM (Ser1981) (clone 7C10D8) mouse MAb (Rockland) at 
the dilution of 1:200 (pH6),  anti-phospho-Chk2 (Thr68) (clone C13C1) rabbit MAb (Cell 
Signaling) at the dilution of 1:200 (pH6), anti-phospho-Chk1 (Ser345) (clone 133D3) rabbit MAb 
(Cell Signaling) at the dilution of 1:150 (pH6), anti-phospho-Wee1 (Ser642) (clone D47G5) rabbit 
MAb (Cell Signaling) at the dilution of 1:100 (pH8), anti-phospho-RPA32 (Ser4/Ser8) rabbit 
polyclonal antibody (Bethyl) at the dilution of 1:100 (pH6). Immunoreactions were revealed by a 
streptavidin-biotin enhanced immunoperoxidase technique (Super Sensitive MultiLink, Leica, 
Milan, Italy) in an automated autostainer (Bond III, Leica). 
To define positive and negative cases a classification comparable to that of our previous studies was 
used.
7,8
 DNA damage markers (γ-H2AX and pRPA32) were classified as high and low/negative 
using the median score of all tumors as the cut-off points. Median percentages of nuclear-
expressing cells for γ-H2AX and pRPA32 were 30% and 40%, respectively. For DDR kinases, 
samples were considered positive when ≥20% of the neoplastic cells showed a distinct nuclear 
immunoreactivity of any intensity. Immunoreactivity was evaluated by two investigators blinded to 
treatment outcomes (LR and EM) and discordant cases were reviewed by a third observer (MM and 
SB).  Immunohistochemical staining of two representative cases is presented in Suppl. Figure 1. 
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Targeted DNA Deep Sequencing  
Genomic DNA was extracted from 5µm FFPE tissue sections using the AllPrep DNA/RNA FFPE 
kit (Qiagen, Valencia, CA, USA). To perform the targeted DNA resequencing of ARID1A and 
TP53, a custom panel employing DesignStudio from Illumina was designed. The library was 
prepared using the TruSeq Custom Amplicon Low Input Kit following the manufacturer’s 
instructions. Sequencing was carried out on a NextSeq 500 (Illumina, Inc., San Diego, CA, USA) in 
paired-end mode, sequencing from each side 150 bp. Primary analysis encompassing FASTQ file 
generation, alignment and variant calling was performed on the Illumina BaseSpace Cloud 
environment, using the Truseq Amplicon analysis pipeline version 2.0. TSV files were generated 
from VCFs with the Illumina Variant Studio software. From TSV files, we filtered out low-
coverage (<200x), dbSNP annotated variants (MAF >5%) and mutations that did not lead to an 
amino acid change of the protein. Afterwards, TP53 and ARID1A mutations were further filtered on 
the basis of the following criteria: i) allele frequencies ≥10%, ii) having a COSMIC ID, iii) 
annotated as oncogenic in cBioPortal Version 1.2.5, last accessed on September 21
st
. The 
experimental workflow is summarized in Suppl. Figure 2.   
Statistical Analyses  
The Pearson’s Chi-squared test of independence (2-tailed) or the Fisher Exact test, depending upon 
the size of the groups compared, were employed for investigating the relationship between 
categorical variable. The correlation between DDR biomarkers, when analyzed as continuous 
variables (percentage of nuclear-expressing cancer cells), was assessed with the Pearson's correlation 
coefficient. Survival curves were estimated with the Kaplan-Meier product-limit method and 
compared by log-rank test. Variables potentially affecting PFS and OS were tested in univariate 
Cox proportional hazard models. Multivariate Cox models were built with variables testing 
significant at the univariate analysis and by stepwise regression through backward elimination. The 
related estimates were reported as hazard ratio (HR) and 95% confident interval (CI). Cross-
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validation was used for assessing the robustness of the molecular background of interest 
(H2AX
high
/pATM
high
); univariate Cox analysis was carried out on the group of patients treated in 
phase II trials (training set), and then on the group of patients treated in routine clinical practice 
(validation set). Level of significance was defined as p<0.05. Statistical analyses were carried out 
using SPSS version 21.0 (SPSS Inc., Chicago, Illinois, USA).   
RESULTS  
Baseline characteristics of the patients and expression pattern of DDR biomarkers 
Baseline characteristics of the 110 patients included in the present analysis are summarized in Table 
1. Median age at diagnosis was 60.8 years. Seventy-two (65.5%) patients had metastatic disease, 
whereas 38 (34.5%) patients received chemotherapy for inoperable locally advanced disease. 
Regarding chemotherapy regimens, 68 (61.8%) patients received three-drug regimens, and taxane-
containing chemotherapy was administered to 61 (55.5%) patients. Fifty-six patients were treated in 
prospective phase II trials. Distributions of DDR biomarkers did not significantly differ by 
treatment received in the first-line setting, i.e., number of therapeutic agents and taxane 
administration (data available upon request). We recorded a significant positive association between 
DDR biomarkers (Figure 1, panel A); a significant correlation between the various markers was 
also observed when they were analyzed as continuous variables considering the percentage of 
nuclear-expressing tumor cells (Figure 1, panel B).  
DDR biomarkers and PFS, sensitivity analysis and outliers analysis  
Patients whose tumors had elevated expression levels of γ-H2AX experienced significant shorter 
PFS compared with their negative counterparts (log rank p=0.001) (Figure 2, panel A), and a non 
significant association was observed for pATM (log rank p=0.081) (Figure 2, panel B). A model of 
double positivity (γ-H2AX
high
/pATM
high
) was also significantly associated with shorter PFS (log 
rank p<0.001) (Figure 2, panel C). Similar results emerged from a sensitivity analysis carried out on 
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patients with metastatic disease, thus excluding patients with locally advanced tumors (Suppl. 
Figure 3). In the entire cohort, we did not appreciate any association between pChk1, pWee1, 
pRPA32 and pChk2 and PFS (data available upon request). Nevertheless, a significant association 
was observed between γ-H2AX, pATM and pChk1 expression and negative and positive outliers, 
namely patients in the lowest (PFS<3 months) and highest (PFS>10 months) quartile (N=54), with 
a trend toward statistical significance for pRPA32 (p=0.057, Suppl. Table 2). Thus, an extensive 
activation of upstream branches of the DDR machinery may delineate a fraction of patients with 
intrinsically chemoresistant GC.  
Uni- and multivariate Cox regression models for PFS and OS, cross-validation  
As our results suggested a prominent role of DSB repair avenues in feeding chemoresistance, the γ-
H2AX
high
/pATM
high
 phenotype was verified in uni- and multivariate Cox models for PFS and OS. 
Uni- and multivariate Cox regression analyses revealed that patients with double-positive tumors 
were at increased risk of progression (multivariate Cox: HR 2.23, 95%CI: 1.47-3.40, p<0.001) 
(Table 2). The consistency of the H2AX
high
/pATM
high 
model was further confirmed upon cross-
validation (Suppl. Figure 4). Uni- and multivariate Cox models for OS (Table 3) yielded 
comparable results (univariate Cox: HR 1.71, 95%CI: 1.03-2.86, p=0.039; multivariate Cox 
adjusted for variables significant at univariate analyses: HR 1.87, 95%CI: 1.00-3.50, p=0.050; 
multivariate Cox with stepwise backward elimination: HR: 2.07, 95%CI: 1.20-3.58, p=0.009).     
 
Predictive significance of DDR biomarkers according to TP53 and ARID1A mutations  
Basal DDR activation may stem from the underlying genetic portrait of the disease, as a number of 
frequently-mutated genes in GC were preclinically tied to the activation of the intra-S and G2/M 
checkpoints. To address this issue, targeted deep resequencing was conducted to evaluate TP53 and 
ARID1A mutational status in 90 patients with sufficient biological materials. As shown in Figure 3 
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(panel A), 53% and 47% of the samples harbored TP53 and ARID1A mutations, respectively 
(detailed information in Suppl. Table 3). In order to investigate whether the genetic status of TP53 
and/or ARID1A impacted the predictive ability of the γ-H2AX
high
/pATM
high
 model, univariate Cox 
analyses were carried out in the different genetic contexts. The relationship between the γ-
H2AX
high
/pATM
high
 model and PFS was  independent on TP53, albeit to a borderline significant 
extent in the TP53-mutated setting (p=0.052) (Figure 3, panel B). Likewise, the H2AX
high
/pATM
high
 
model continued to be associated with an increased risk of disease progression in the ARID1A wild-
type background. Conversely, this relationship was lost in the ARID1A-mutated setting (Figure 3, 
panel B).   
DISCUSSION 
We herein examined the expression pattern of central orchestrators of the DDR response in a 
relatively large series of advanced GC patients treated with first-line therapy. Approximately half of 
these patients received chemotherapy in prospective phase II trials.
10-13
  As activation of the ATM-
Chk2/ATR-Chk1-Wee1 cascade may be related to, or enforced by, genetic events altering cell cycle 
progression and DNA repair efficiency, the mutational status of top-ranking mutated genes in GC 
(TP53 and ARID1A) was assessed. Our results suggest that: i) a subset of GC is characterized by a 
robust DDR activation, ii) activation of the system that signals the presence of DSBs may be 
detrimental for these patients conferring chemoresistant features, as denoted by uni- and 
multivariate Cox models for PFS and OS, and iii) the clinical relevance of this process may be 
independent on TP53 status, whereas it seemed affected by protein-damaging ARID1A mutations. 
Our study, which is hypothesis-generating in nature, raised a number of points that may streamline 
the identification of efficient DDR-related predictive factors. In the search for molecular 
determinants anticipating the benefits patients receive from chemotherapy, the focus was mostly 
placed on single effectors acting within a specific repair avenue deputed to correct a given type of 
genetic lesion.
16,17
  Our results suggest that molecular mechanisms through which cancer cells sense 
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DNA damage and the way this information is transmitted/amplified should not be underestimated in 
future investigations.   
The lesson learned from preclinical investigations striving to elucidate how cancer cells exploit the 
DDR to survive chemotherapy is that protein-protein interactions should be viewed in light of 
genetic contexts that, at the level of protein function, intersect these communications.
18,19
  For 
instance, pharmacological inhibitors of upstream DDR kinases were originally advocated as 
synthetically lethal therapeutics for targeting p53-defective tumors.
18,19
   We neither observed an 
impact of TP53 mutations on the predictive ability of DDR markers, nor any association between 
TP53 status and the investigated molecular endpoints was found (data available upon request). 
Albeit these data may question the idea of an intra-S/G2-M checkpoint dependency of p53-defective 
tumors, two not mutually exclusive molecular mechanisms deserve mention. First, TP53 mutations 
not invariably result in a defective protein, but rather some missense mutations (overall accounting 
for ~75% of all TP53 mutations) encode for a protein with oncogenic potential (gain-of-function 
mutations).
20
   Even though these mutated p53 forms exert a dominant-negative effect on wild-type 
p53, they also endow the new protein with tumor-promoting abilities.
20
  Second, GC harbors 
amplification of cyclins (e.g. CCNE1 and CCND1) and cyclin-dependent kinases (e.g. CDK6) that 
drive cells from G1 into S phase, suggesting the existence of another level of deregulation at the G1-
S transition beyond loss of p53 function.
9
  Tailored preclinical investigations are warranted for the 
correct interpretation of how the different spectrum of TP53 lesions, together with other defects in 
the G1-S transition machinery, lead to intra-S and G2/M checkpoint dependency and fuel 
chemoresistance.  
Next, the tumor suppressor ARID1A, a subunit of the SWI/SNF chromatin remodeling complex, 
was identified as frequently mutated in a broad spectrum of tumors.
21
 It was recently demonstrated 
that ARID1A is recruited to DNA DSBs via ATM/ATR signaling where it facilitates the processing 
of DNA lesions.
22
 ARID1A-deficient cells displayed impaired initiation and maintenance of the G2-
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M checkpoint and overall a suboptimal response to DSBs. Moreover, ARID1A suppression resulted 
in reduced non-homologous end joining activity and sensitized cell lines to cytotoxic agents. 
23
 As 
we did not observe any association between DDR markers and an increased risk of disease 
progression in the ARID1A-mutated setting, we speculate that defective ARID1A function may 
interfere with molecular mechanisms conferring chemoresistant traits. In order to provide further 
ground to this observation, we strive to establish a collection of patient-derived cancer (stem) cell 
lines and xenografts. There are several reasons behind this choice: i) even though our data suggest a 
connection between ARID1A status, the DDR and sensitivity/resistance to chemotherapy, we were 
unable to conduct mechanistic in vitro studies given the limited availability of commercially 
available (e.g. ATCC) GC cell lines carrying ARID1A mutations, ii)  prospectively isolated patient-
derived GC cells and xenografts are expected to better recapitulate the molecular portrait of the 
parental tumors compared with commercial cell lines,
24
 which expose investigators to a number of 
potential biases (e.g. cross-contamination, molecular artifacts stemming from multiple passages in 
culture) and whose clinical usefulness is the focus of intense debate in the scientific community.
25
 
Moreover, prospective isolation and characterization of patient-derived GC cells will enable us to 
combine mechanistic and correlative studies, iii) the majority of commercially available GC cell 
lines were obtained from patients of Asian ethnicity, and it is known that non-negligible differences 
exist between GC arising in Asians and Caucasians, both at the molecular and clinical level. 
26-28
  
A third level of genetic characterization that should be pursued refers to oncogene-induced 
replication stress. This condition is characterized by increased numbers of stalled or collapsed 
replication forks that elicits an ATM-ATR-dependent response.
3
 MYC overexpression/amplification 
is among the best characterized condition underlying oncogene-induced replication stress, and 
inhibition of DDR kinases was proposed as a synthetic lethality-based approach for targeting MYC-
driven tumors.
29,30
   Approximately 15% of GCs carry MYC amplification/mutation and a “target of 
MYC activation” signature was found to be active in all the four GC subtypes.
9 
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A mention deserves the positive association in the expression of the investigated markers (Figure 
1), which suggests a robust activation of the DDR response in a subset of GC patients. This finding 
potentially holds therapeutic perspective in light of the number of cell cycle checkpoint inhibitors 
that have entered clinical development over the past years.
18
 Even though results from pioneering 
clinical trials dampened the expectations around these compounds,
18
 these studies were weakened 
by lack of biomarker analysis. Our study may represent a first step toward delineating  the target 
population for clinical trials with cell cycle checkpoint inhibitors, enforcing the concept that 
extensive DDR pathway analysis should be carried out both at the protein and genetic level to 
streamline the development of these compounds.    
Finally, our interest toward the identification of DDR-linked predictive biomarkers prompted us to 
initiate a further level of molecular characterization, with special emphasis being placed on the 
Fanconi Anemia (FA) pathway. The FA pathway is involved in DNA interstrand crosslink (ICL) 
repair,
31
 and its over-activation was found to be a shared trait across the four molecular subtypes 
identified by the TCGA.
9
 To this end, we activated a multicenter, retrospective study in an 
expanded case series with the aim of investigating the predictive significance of various FA 
pathway markers. More specifically, we planned the study of FA pathway components involved in 
lesion recognition (e.g. FANCM),  components of the FA core complex (e.g. FANCA to FANCT), 
and the ERCC4-ERCC1 complex, which is central in unhooking ICL lesions.
31-33
 
In conclusion, our data pointed to the activation of upstream regulators of the DDR machinery as 
potential biomarkers for predicting the efficacy of chemotherapy in GC patients. Prospective 
validation of these encouraging findings, together with a deeper characterization of genetic events 
tied to the processing of DNA lesions, is advised in order to gain a better understanding on how this 
information can be transferred into the clinical setting.    
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Figure legends 
Figure 1: Relationship between the expression levels of six DDR biomarkers (γ-H2AX, pATM, 
pChk2, pRPA32, pChk1 and pWee1). Associations are shown in the oncoprint in panel A, 
correlations in panel B (N=110).   
Figure 2: Kaplan-Meier survival curves of progression-free survival. γ-H2AX
high
 vs γ-H2AX
low/neg 
(A); pATM
high
 vs pATM
low/neg 
(B); γ-H2AX
high
/pATM
high
 vs single-positive tumors/double-negative 
tumors (C) (N=110). 
Figure 3: Panel A: Oncoprint showing  the distribution and type of TP53 and ARID1A mutations in 
90 gastric cancer patients. Panel B: Forest plot for subgroup analysis displaying the relationship 
between the γ-H2AX
high
/pATM
high 
model and progression-free survival in the different TP53 and 
ARID1A genetic backgrounds (wild-type and mutated). 
Supplementary Figure 1: Representative examples of immunohistochemical expression of six 
DNA damage and repair biomarkers in gastric cancer patients. Upper panel: a triple-positive tumor 
with nuclear γ-H2AX(a), pATM (b), and pChk2 (c) immunoreactivity. Lower panel: a triple-
positive tumor with nuclear  pChk1 (d),  pRPA32 (e) and pWee1(f) immunoreactivity.  
Supplementary Figure 2: Experimental workflow for filtering TP53 and ARID1A mutations in 90 
gastric cancer patients.  
Supplementary Figure 3: Kaplan-Meier survival curves of progression-free survival in patients 
with metastatic disease. γ-H2AX
high
 vs γ-H2AX
low/neg 
(A); γ-H2AX
high
/pATM
high
 vs single-positive 
tumors/double-negative tumors (B) (N= 72). 
Supplementary Figure 4: Univariate Cox models for progression-free survival (cross-validation) 
in the group of patients treated in phase II trials (training set) and in the group who received 
chemotherapy in real-world clinical practice (validation set).  
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Table 1: Baseline characteristics of gastric cancer patients included in this study (N=110) 
 
Characteristics  N (%) 
Age at diagnosis Median (min-max) [IQ range] 60.8 (28-79) [51.3-67.4] 
Gender 
Male 
Female 
58 (52.7) 
52 (47.3) 
ECOG PS 
0 
1-2 
58 (52.7) 
52 (47.3) 
Stage 
Locally Advanced 
Metastatic 
38 (34.5) 
72 (65.5) 
Previous Surgery 
No 
Yes 
53 (48.2) 
57 (51.8) 
Neoadjuvant/Adjuvant 
chemotherapy 
No 
Yes 
82 (74.5) 
28 (25.5) 
Lauren classification 
Intestinal 
Diffuse 
Mixed 
50 (45.5) 
48 (43.6) 
12 (10.9) 
Grade 
G2 
G3 
Unknown 
24 (21.8) 
82 (74.5) 
4 (3.7) 
Localization  
Esophagogastric Junction (EOJ) 
Stomach 
10 (9.1) 
100 (90.9) 
Agents (N) 
2 
3 
42 (38.2) 
68 (61.8) 
Taxanes 
No 
Yes 
49 (44.5) 
61 (55.5) 
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Table 2 : Uni- and multivariate Cox regression models for PFS (N=110) 
  Univariate Cox 
regression model 
Multivariate Cox 
regression model
§
 
Multivariate Cox 
regression model** 
  HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value 
γ-H2AX
pos
/pATM
pos
 positive vs 
other  
2.23 (1.47-3.40) <0.001 
2.11 (1.35-3.28) 0.001 
  2.23 (1.47-3.40) <0.001 
ECOG-PS 1-2 vs 0 1.28 (0.85-1.92) 0.238     
Stage Met vs loc adv 1.23 (0.80-1.89) 0.344     
Localization  Stomach vs 
EOJ 
0.66 (0.33-1.33) 0.243 
    
N° metastatic sites 2-3 vs 1 1.54 (0.99-2.37) 0.052 1.22 (0.77-1.93) 0.390   
Peritoneal metastasis Yes vs No 0.70 (0.47-1.06) 0.092     
Taxanes Yes vs No 0.88 (0.58-1.33) 0.551     
§
 Adjusted for  variables significant at the univariate analysis. 
**Backward stepwise exclusion. 
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Table 3 : Uni- and multivariate Cox regression models for OS ( N=110). 
  Univariate Cox 
regression model 
Multivariate Cox 
regression model
§
 
Multivariate Cox 
regression model** 
  HR (95%CI) 
p-value 
HR (95%CI) p-
value 
HR (95%CI) p-value 
γ-H2AX
pos
/pATM
pos
 positive 
vs other 
1.71 (1.03-2.86) 0.039 
1.87 (1.00-3.50) 0.050 2.07 (1.20-3.58) 0.009 
ECOG-PS 1-2 vs 0 1.05 (0.62-1.75) 0.860     
Stage Met vs 
loc adv 
1.17 (0.68-2.01) 0.574 
    
Localization  Stomach 
vs EOJ 
0.54 (0.23-1.28) 0.161 
    
N° metastatic sites 2-3 vs 1 1.67 (0.99-2.79) 0.054 1.24 (0.65-2.35) 0.515   
Peritoneal metastasis Yes vs No 0.69 (0.41-1.15) 0.156     
Taxanes Yes vs No 0.56 (0.33-0.93) 0.027 0.55 (0.31-0.99) 0.048 0.54 (0.30-0.97) 0.041 
Response to first-line 
therapy 
Yes vs No 
0.42 (0.25-0.73) 0.002 
0.48 (0.26-0.88) 0.018 0.50 (0.28-0.90) 0.022 
2nd line 
chemotherapy 
Yes vs No 
0.27 (0.15-0.47) <0.001 
0.41 (0.23-0.73) 0.002 0.41 (0.23-0.72) 0.002 
§
 Adjusted for the variables significant at the univariate analysis. 
**Backward stepwise exclusion. 
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Figure 1: Relationship between the expression levels of six DDR biomarkers (γ-H2AX, pATM, pChk2, 
pRPA32, pChk1 and pWee1). Associations are shown in the oncoprint in panel A, correlations in panel B 
(N=110).    
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Figure 2: Kaplan-Meier survival curves of progression-free survival. γ-H2AXhigh vs γ-H2AXlow/neg (A); 
pATMhigh vs pATMlow/neg (B); γ-H2AXhigh/pATMhigh vs single-positive tumors/double-negative tumors (C) 
(N=110).  
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Figure 3: Panel A: Oncoprint showing  the distribution and type of TP53 and ARID1A mutations in 90 gastric 
cancer patients. Panel B: Forest plot for subgroup analysis displaying the relationship between the γ-
H2AXhigh/pATMhigh model and progression-free survival in the different TP53 and ARID1A genetic 
backgrounds (wild-type and mutated).  
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